Form 13-F position report Filing season in progress

REGENERON PHARMACEUTICALS

Reported by Bellecapital International Ltd

Company profile Manager portfolio Source filing
REGN CUSIP 75886F107 Manager CIK 0001600152
Latest reported change

Reported 28,462 shares, up 868 (3.1%) from the prior quarter.

Reported value 25.4%; share count 3.1% vs. the prior quarter.

Added
% of reported 13F value 3.16% This manager · Q3 2026
Shares 28,462 Quarter-end amount reported
Reported value $21,581,881 Fair value at quarter end
Consecutive quarters held 18 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q3 2026 Added 28,462 +868 (3.1%) 3.16% $21,581,881 2026-10-21
Q2 2026 Added 27,594 +3,308 (13.6%) 2.75% $17,205,963 2026-07-22
Q1 2026 Added 24,286 +1,177 (5.1%) 3.39% $18,764,335 2026-04-17
Q4 2025 Reduced 23,109 -4,670 (-16.8%) 3.17% $17,837,144 2026-02-02
Q3 2025 Added 27,779 +2,276 (8.9%) 2.52% $15,619,298 2025-10-17
Q2 2025 Added 25,503 +6,283 (32.7%) 2.38% $13,389,075 2025-07-29
Q1 2025 Reduced 19,220 -380 (-1.9%) 2.41% $12,189,901 2025-04-16
Q4 2024 Added 19,600 +6,002 (44.1%) 2.47% $13,961,668 2025-02-06
Q3 2024 Added 13,598 +226 (1.7%) 2.84% $14,294,762 2024-10-21
Q2 2024 Added 13,372 +192 (1.5%) 2.98% $14,054,373 2024-07-19
Q1 2024 Added 13,180 +158 (1.2%) 2.8% $12,685,618 2024-05-03
Q4 2023 Added 13,022 +502 (4.0%) 2.59% $11,437,092 2024-01-22
Q3 2023 Added 12,520 +151 (1.2%) 2.58% $10,303,459 2023-10-17
Q2 2023 Reduced 12,369 -4 (0.0%) 2.15% $8,887,621 2023-07-07
Q1 2023 Added 12,373 +206 (1.7%) 2.53% $10,166,523 2023-04-25
Q4 2022 Added 12,167 +168 (1.4%) 2.47% $8,778,369 2023-02-10
Q3 2022 Added 11,999 +2,648 (28.3%) 2.52% $8,266,000 2022-11-07
Q2 2022 New 9,351 +9,351 (0.0%) 1.54% $5,528,000 2022-07-27
Institutional context

Who else reported the position

490 managers reported REGENERON PHARMACEUTICALS for Q3 2026 so far.

Manager Activity Shares Change % of reported 13F Reported value Tenure
Robeco Institutional Asset Management B V Reduced 402,958 -57,644 0.37% $305,550,967 54 qtrs
Sumitomo Mitsui Trust Holdings Inc Reduced 278,120 -4,079 0.12% $210,890,052 54 qtrs
Swedbank AB Reduced 188,572 -1,276 0.12% $142,988,492 23 qtrs
KBC Group NV Added 188,496 +8,988 0.3% $142,930,000 54 qtrs
MCDONALD CAPITAL INVESTORS INC CA Reduced 172,649 -20,389 10.75% $130,914,557 34 qtrs
Mirae Asset Global Investments Co Ltd Added 126,572 +32,940 0.17% $95,975,750 49 qtrs
ProShare Advisors LLC Reduced 117,034 -2,206 0.13% $88,743,373 54 qtrs
DekaBank Deutsche Girozentrale Reduced 87,375 -123,832 0.07% $65,860,000 54 qtrs
PINNACLE ASSOCIATES LTD Added 81,285 +38 0.69% $61,635,679 54 qtrs
NEW YORK STATE TEACHERS RETIREMENT SYSTEM Reduced 78,990 -5,188 0.11% $59,896,000 54 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
October 21, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
0
None
28,462

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.